Global Veterinary Animal Vaccines Market (. By Type- Monovalent Vaccines, Multivalent Vaccines, Procine Vaccines, Poultry Vaccines, Livestock Vaccines, Companion Animal Vaccines, Aquaculture Vaccines and other Animal Vaccines. By Disease- Porcine, Livestock, Companion Animal Disease, Aquaculture, Influenza, Dengue, Rotavirus, Hepatitis, and other Diseases. By End-Users- Pediatrics, and Adults and others. By Technology- Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, and other Vaccines.) – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017 – 2025”
The report covers the analysis and forecast of the Veterninary animal vaccines market on global as well as regional level. The study provides historic data of 2016 along with the forecast for the period between 2017 and 2025 based on revenue (US$ Mn).
The study provides a detailed view of the Veterninary animal vaccines market, by segmenting it based on by type, by disease, by end-user, by technology, and regional demand. Vaccination helps the living beings from getting affected by diseases. Increasing diseases and adoption of pets is increasing the demand for vaccine market. Development and launch of new products by major players present in the market, is also expected to make the Veterninary animal vaccines market more demanding in the near future.
Regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Middle East and Africa and Latin America. The segmentation also includes by type, by disease, by end-user, by technology. These include different business strategies adopted by the leading players and their recent developments.
A comprehensive analysis of the market dynamics that is inclusive of market drivers, restraints, and opportunities is part of the report. Additionally, the report includes potential opportunities in the Veterninary animal vaccines market at the global and regional levels. Market dynamics are the factors which impact the market growth, so their analysis helps understand the ongoing trends of the global market. Therefore, the report provides the forecast of the global market for the period from 2017 to 2025, along with offering an inclusive study of the Veterninary animal vaccines market.
The report provides the size of the Veterninary animal vaccines market in 2017 and the forecast for the next eight years up to 2025. The size of the global Veterninary animal vaccines market is provided in terms of revenue. Market revenue is defined in US$ Mn. The market dynamics prevalent in North America, Europe, Asia Pacific, Middle East and Africa and Latin America has been taken into account in estimating the growth of the global market.
Market estimates for this study have been based on revenue being derived through regional pricing trends. The Veterninary animal vaccines market has been analyzed based on expected demand. Bottom-up approach is done to estimate the global revenue of the Veterninary animal vaccines market, split into regions. Based on type, disease, end-user, technology, the individual revenues from all the regions is summed up to achieve the global revenue for Veterninary animal vaccines market. Companies were considered for the market share analysis, based on their innovation and application and revenue generation. In the absence of specific data related to the sales of Veterninary animal vaccines by several privately held companies, calculated assumptions have been made in view of the company’s penetration and regional presence.
The report covers a detailed competitive outlook that includes the market share and company profiles of key players operating in the global market. Key players profiled in the report include Pfizer, Inc, GlaxoSmithKline Plc, Merck and co., Inc, Sanofi Pasteur SA, CSL Limited, Emergent BioSolutions, Inc, Johnson And Johnson, Medimmune, LLC, Atellas Pharma, Inc, Serum Institute of India, Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company, Limited, and others.
The global Veterninary animal vaccines market has been segmented into:
Global Veterinary Animal Vaccines Market: By Type
The study provides a detailed view of the Veterninary animal vaccines market, by segmenting it based on by type, by disease, by end-user, by technology, and regional demand. Vaccination helps the living beings from getting affected by diseases. Increasing diseases and adoption of pets is increasing the demand for vaccine market. Development and launch of new products by major players present in the market, is also expected to make the Veterninary animal vaccines market more demanding in the near future.
Regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Middle East and Africa and Latin America. The segmentation also includes by type, by disease, by end-user, by technology. These include different business strategies adopted by the leading players and their recent developments.
A comprehensive analysis of the market dynamics that is inclusive of market drivers, restraints, and opportunities is part of the report. Additionally, the report includes potential opportunities in the Veterninary animal vaccines market at the global and regional levels. Market dynamics are the factors which impact the market growth, so their analysis helps understand the ongoing trends of the global market. Therefore, the report provides the forecast of the global market for the period from 2017 to 2025, along with offering an inclusive study of the Veterninary animal vaccines market.
The report provides the size of the Veterninary animal vaccines market in 2017 and the forecast for the next eight years up to 2025. The size of the global Veterninary animal vaccines market is provided in terms of revenue. Market revenue is defined in US$ Mn. The market dynamics prevalent in North America, Europe, Asia Pacific, Middle East and Africa and Latin America has been taken into account in estimating the growth of the global market.
Market estimates for this study have been based on revenue being derived through regional pricing trends. The Veterninary animal vaccines market has been analyzed based on expected demand. Bottom-up approach is done to estimate the global revenue of the Veterninary animal vaccines market, split into regions. Based on type, disease, end-user, technology, the individual revenues from all the regions is summed up to achieve the global revenue for Veterninary animal vaccines market. Companies were considered for the market share analysis, based on their innovation and application and revenue generation. In the absence of specific data related to the sales of Veterninary animal vaccines by several privately held companies, calculated assumptions have been made in view of the company’s penetration and regional presence.
The report covers a detailed competitive outlook that includes the market share and company profiles of key players operating in the global market. Key players profiled in the report include Pfizer, Inc, GlaxoSmithKline Plc, Merck and co., Inc, Sanofi Pasteur SA, CSL Limited, Emergent BioSolutions, Inc, Johnson And Johnson, Medimmune, LLC, Atellas Pharma, Inc, Serum Institute of India, Bavarian Nordic, Mitsubishi Tanabe Pharma Corporation, Daiichi Sankyo Company, Limited, and others.
The global Veterninary animal vaccines market has been segmented into:
Global Veterinary Animal Vaccines Market: By Type
- Monovalent Vaccines
- Multivalent Vaccines
- Procine Vaccines
- Poultry Vaccines
- Livestock Vaccines
- Bovine Vaccines
- Small ruminant Vaccines
- Companion animal Vaccines
- Canine Vaccines
- Fenine Vaccines
- Aquaculture Vaccines
- Other animal Vaccines
- Porcine
- Livestock
- Bovine
- Small ruminant
- Companion animal disease
- Canine
- Fenine
- Aquaculture
- Influenza
- Dengue
- Rotavirus
- Hepatitis
- Others
- Pediatrics
- Adults
- Live attenuated Vaccines
- Inactivated Vaccines
- Toxoid Vaccines
- Recombinant Vaccines
- Other Vaccines
- North America
- The U.S.
- Canada
- Mexico
- Europe
- U.K.
- France
- Germany
- Italy
- Rest of Europe
- Asia Pacific
- India
- China
- Japan
- Rest of Asia Pacific
- Middle East and Africa
- South Africa
- Rest of Middle East and Africa
- Latin America
- Brazil
- Rest of Latin America
1 INTRODUCTION
1.1 MARKET SEGMENTATION
2 RESEARCH METHODOLOGY
2.1 ECOSYSTEM OF VATENIARY ANIMAL VACCINES MARKET
2.2 TOP-DOWN APPROACH
2.3 BOTTOM-UP APPROACH
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 GLOBAL VATENIARY ANIMAL VACCINES MARKET SNAPSHOT
3.2 GLOBAL VATENIARY ANIMAL VACCINES MARKET REVENUE, 2017– 2025(US$ MN)
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 KEY TRENDS ANALYSIS
4.3 PRODUCT DEVELOPMENT AND DIVERSIFICATION ANALYSIS
4.4 PORTERS FIVE FORCE ANALYSIS
4.5 VALUE CHAIN ANALYSIS
4.6 COMPETITIVE LANDSCAPE
4.7 COMPANY MARKET SHARE ANALYSIS
4.8 EXPANSION STRATEGIES ADOPTED BY LEADING PLAYERS
5 GLOBAL VATENIARY ANIMAL VACCINES MARKET, BY TYPE
5.1 OVERVIEW
5.2 MONOVALENT VACCINES
5.3 MULTIVALENT VACCINES
5.4 PROCINE VACCINES
5.5 POULTRY VACCINES
5.6 LIVESTOCK VACCINES
5.6.1 BOVINE VACCINES
5.6.2 SMALL RUMINANT VACCINES
5.7 COMPANION ANIMAL VACCINES
5.7.1 CANINE VACCINES
5.7.2 FENINE VACCINES
5.8 AQUACULTURE VACCINES
5.9 OTHER ANIMAL VACCINES
6 GLOBAL VATENIARY ANIMAL VACCINES MARKET, BY DISEASE
6.1 OVERVIEW
6.2 PORCINE
6.3 LIVESTOCK
6.3.1 BOVINE
6.3.2 SMALL RUMINANT
6.4 COMPANION ANIMAL DISEASE
6.4.1 CANINE
6.4.2 FENINE
6.5 AQUACULTURE
6.6 INFLUENZA
6.7 DENGUE
6.8 ROTAVIRUS
6.9 HEPATITIS
6.10 OTHERS
7 GLOBAL VATENIARY ANIMAL VACCINES MARKET, BY END-USER
7.1 OVERVIEW
7.2 PEDIATRICS
7.3 ADULTS
8 GLOBAL VATENIARY ANIMAL VACCINES MARKET, BY TECHNOLOGY
8.1 OVERVIEW
8.2 LIVE ATTENUATED VACCINES
8.3 INACTIVATED VACCINES
8.4 TOXOID VACCINES
8.5 RECOMBINANT VACCINES
8.6 OTHER VACCINES
9 GLOBAL VATENIARY ANIMAL VACCINES MARKET, BY GEOGRAPHY
9.1 NORTH AMERICA
9.1.1 MARKET DYNAMICS
9.1.1.1 DRIVERS
9.1.1.2 RESTRAINTS
9.1.1.3 OPPORTUNITY
9.1.2 U.S.
9.1.3 CANADA
9.1.4 MEXICO
9.2 EUROPE
9.2.1 MARKET DYNAMICS
9.2.1.1 DRIVERS
9.2.1.2 RESTRAINTS
9.2.1.3 OPPORTUNITY
9.2.2 U.K.
9.2.3 FRANCE
9.2.4 GERMANY
9.2.5 SPAIN
9.2.6 REST OF EUROPE
9.3 ASIA PACIFIC
9.3.1 MARKET DYNAMICS
9.3.1.1 DRIVERS
9.3.1.2 RESTRAINTS
9.3.1.3 OPPORTUNITY
9.3.2 INDIA
9.3.3 CHINA
9.3.4 JAPAN
9.3.5 REST OF ASIA PACIFIC
9.4 MIDDLE EAST AND AFRICA
9.4.1 MARKET DYNAMICS
9.4.1.1 DRIVERS
9.4.1.2 RESTRAINTS
9.4.1.3 OPPORTUNITY
9.4.2 SOUTH AFRICA
9.4.3 REST OF MIDDLE EAST AND AFRICA
9.5 LATIN AMERICA
9.5.1 MARKET DYNAMICS
9.5.1.1 DRIVERS
9.5.1.2 RESTRAINTS
9.5.1.3 OPPORTUNITY
9.5.2 BRAZIL
9.5.3 REST OF LATIN AMERICA
10 GLOBAL VATENIARY ANIMAL VACCINES MARKET, BY COMPANY
10.1 INTRODUCTION
10.2 PFIZER, INC
10.2.1 BUSINESS OVERVIEW
10.2.2 PRODUCTS & SERVICES
10.2.3 KEY STRATEGY
10.2.4 RECENT DEVELOPMENTS
10.2.5 SWOT ANALYSIS
10.3 GLAXOSMITHKLINE PLC.
10.3.1 BUSINESS OVERVIEW
10.3.2 PRODUCTS & SERVICES
10.3.3 KEY STRATEGY
10.3.4 RECENT DEVELOPMENTS
10.3.5 SWOT ANALYSIS
10.4 MERCK AND CO., INC.
10.4.1 BUSINESS OVERVIEW
10.4.2 PRODUCTS & SERVICES
10.4.3 KEY STRATEGY
10.4.4 RECENT DEVELOPMENTS
10.4.5 SWOT ANALYSIS
10.5 SANOFI PASTEUR SA
10.5.1 BUSINESS OVERVIEW
10.5.2 PRODUCTS & SERVICES
10.5.3 KEY STRATEGY
10.5.4 RECENT DEVELOPMENTS
10.5.5 SWOT ANALYSIS
10.6 CSL LIMITED
10.6.1 BUSINESS OVERVIEW
10.6.2 PRODUCTS & SERVICES
10.6.3 KEY STRATEGY
10.6.4 RECENT DEVELOPMENTS
10.6.5 SWOT ANALYSIS
10.7 EMERGENT BIOSOLUTIONS, INC
10.7.1 BUSINESS OVERVIEW
10.7.2 PRODUCTS & SERVICES
10.7.3 KEY STRATEGY
10.7.4 RECENT DEVELOPMENTS
10.7.5 SWOT ANALYSIS
10.8 JOHNSON AND JOHNSON
10.8.1 BUSINESS OVERVIEW
10.8.2 PRODUCTS & SERVICES
10.8.3 KEY STRATEGY
10.8.4 RECENT DEVELOPMENTS
10.8.5 SWOT ANALYSIS
10.9 MEDIMMUNE, LLC
10.9.1 BUSINESS OVERVIEW
10.9.2 PRODUCTS & SERVICES
10.9.3 KEY STRATEGY
10.9.4 RECENT DEVELOPMENTS
10.9.5 SWOT ANALYSIS
10.10 ATELLAS PHARMA, INC
10.10.1 BUSINESS OVERVIEW
10.10.2 PRODUCTS & SERVICES
10.10.3 KEY STRATEGY
10.10.4 RECENT DEVELOPMENTS
10.10.5 SWOT ANALYSIS
10.11 SERUM INSTITUTE OF INDIA
10.11.1 BUSINESS OVERVIEW
10.11.2 PRODUCTS & SERVICES
10.11.3 KEY STRATEGY
10.11.4 RECENT DEVELOPMENTS
10.11.5 SWOT ANALYSIS
10.12 BAVARIAN NORDIC
10.12.1 BUSINESS OVERVIEW
10.12.2 PRODUCTS & SERVICES
10.12.3 KEY STRATEGY
10.12.4 RECENT DEVELOPMENTS
10.12.5 SWOT ANALYSIS
10.13 MITSUBISHI TANABE PHARMA CORPORATION
10.13.1 BUSINESS OVERVIEW
10.13.2 PRODUCTS & SERVICES
10.13.3 KEY STRATEGY
10.13.4 RECENT DEVELOPMENTS
10.13.5 SWOT ANALYSIS
10.14 DAIICHI SANKYO COMPANY, LIMITED
10.14.1 BUSINESS OVERVIEW
10.14.2 PRODUCTS & SERVICES
10.14.3 KEY STRATEGY
10.14.4 RECENT DEVELOPMENTS
10.14.5 SWOT ANALYSIS
1.1 MARKET SEGMENTATION
2 RESEARCH METHODOLOGY
2.1 ECOSYSTEM OF VATENIARY ANIMAL VACCINES MARKET
2.2 TOP-DOWN APPROACH
2.3 BOTTOM-UP APPROACH
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 GLOBAL VATENIARY ANIMAL VACCINES MARKET SNAPSHOT
3.2 GLOBAL VATENIARY ANIMAL VACCINES MARKET REVENUE, 2017– 2025(US$ MN)
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 KEY TRENDS ANALYSIS
4.3 PRODUCT DEVELOPMENT AND DIVERSIFICATION ANALYSIS
4.4 PORTERS FIVE FORCE ANALYSIS
4.5 VALUE CHAIN ANALYSIS
4.6 COMPETITIVE LANDSCAPE
4.7 COMPANY MARKET SHARE ANALYSIS
4.8 EXPANSION STRATEGIES ADOPTED BY LEADING PLAYERS
5 GLOBAL VATENIARY ANIMAL VACCINES MARKET, BY TYPE
5.1 OVERVIEW
5.2 MONOVALENT VACCINES
5.3 MULTIVALENT VACCINES
5.4 PROCINE VACCINES
5.5 POULTRY VACCINES
5.6 LIVESTOCK VACCINES
5.6.1 BOVINE VACCINES
5.6.2 SMALL RUMINANT VACCINES
5.7 COMPANION ANIMAL VACCINES
5.7.1 CANINE VACCINES
5.7.2 FENINE VACCINES
5.8 AQUACULTURE VACCINES
5.9 OTHER ANIMAL VACCINES
6 GLOBAL VATENIARY ANIMAL VACCINES MARKET, BY DISEASE
6.1 OVERVIEW
6.2 PORCINE
6.3 LIVESTOCK
6.3.1 BOVINE
6.3.2 SMALL RUMINANT
6.4 COMPANION ANIMAL DISEASE
6.4.1 CANINE
6.4.2 FENINE
6.5 AQUACULTURE
6.6 INFLUENZA
6.7 DENGUE
6.8 ROTAVIRUS
6.9 HEPATITIS
6.10 OTHERS
7 GLOBAL VATENIARY ANIMAL VACCINES MARKET, BY END-USER
7.1 OVERVIEW
7.2 PEDIATRICS
7.3 ADULTS
8 GLOBAL VATENIARY ANIMAL VACCINES MARKET, BY TECHNOLOGY
8.1 OVERVIEW
8.2 LIVE ATTENUATED VACCINES
8.3 INACTIVATED VACCINES
8.4 TOXOID VACCINES
8.5 RECOMBINANT VACCINES
8.6 OTHER VACCINES
9 GLOBAL VATENIARY ANIMAL VACCINES MARKET, BY GEOGRAPHY
9.1 NORTH AMERICA
9.1.1 MARKET DYNAMICS
9.1.1.1 DRIVERS
9.1.1.2 RESTRAINTS
9.1.1.3 OPPORTUNITY
9.1.2 U.S.
9.1.3 CANADA
9.1.4 MEXICO
9.2 EUROPE
9.2.1 MARKET DYNAMICS
9.2.1.1 DRIVERS
9.2.1.2 RESTRAINTS
9.2.1.3 OPPORTUNITY
9.2.2 U.K.
9.2.3 FRANCE
9.2.4 GERMANY
9.2.5 SPAIN
9.2.6 REST OF EUROPE
9.3 ASIA PACIFIC
9.3.1 MARKET DYNAMICS
9.3.1.1 DRIVERS
9.3.1.2 RESTRAINTS
9.3.1.3 OPPORTUNITY
9.3.2 INDIA
9.3.3 CHINA
9.3.4 JAPAN
9.3.5 REST OF ASIA PACIFIC
9.4 MIDDLE EAST AND AFRICA
9.4.1 MARKET DYNAMICS
9.4.1.1 DRIVERS
9.4.1.2 RESTRAINTS
9.4.1.3 OPPORTUNITY
9.4.2 SOUTH AFRICA
9.4.3 REST OF MIDDLE EAST AND AFRICA
9.5 LATIN AMERICA
9.5.1 MARKET DYNAMICS
9.5.1.1 DRIVERS
9.5.1.2 RESTRAINTS
9.5.1.3 OPPORTUNITY
9.5.2 BRAZIL
9.5.3 REST OF LATIN AMERICA
10 GLOBAL VATENIARY ANIMAL VACCINES MARKET, BY COMPANY
10.1 INTRODUCTION
10.2 PFIZER, INC
10.2.1 BUSINESS OVERVIEW
10.2.2 PRODUCTS & SERVICES
10.2.3 KEY STRATEGY
10.2.4 RECENT DEVELOPMENTS
10.2.5 SWOT ANALYSIS
10.3 GLAXOSMITHKLINE PLC.
10.3.1 BUSINESS OVERVIEW
10.3.2 PRODUCTS & SERVICES
10.3.3 KEY STRATEGY
10.3.4 RECENT DEVELOPMENTS
10.3.5 SWOT ANALYSIS
10.4 MERCK AND CO., INC.
10.4.1 BUSINESS OVERVIEW
10.4.2 PRODUCTS & SERVICES
10.4.3 KEY STRATEGY
10.4.4 RECENT DEVELOPMENTS
10.4.5 SWOT ANALYSIS
10.5 SANOFI PASTEUR SA
10.5.1 BUSINESS OVERVIEW
10.5.2 PRODUCTS & SERVICES
10.5.3 KEY STRATEGY
10.5.4 RECENT DEVELOPMENTS
10.5.5 SWOT ANALYSIS
10.6 CSL LIMITED
10.6.1 BUSINESS OVERVIEW
10.6.2 PRODUCTS & SERVICES
10.6.3 KEY STRATEGY
10.6.4 RECENT DEVELOPMENTS
10.6.5 SWOT ANALYSIS
10.7 EMERGENT BIOSOLUTIONS, INC
10.7.1 BUSINESS OVERVIEW
10.7.2 PRODUCTS & SERVICES
10.7.3 KEY STRATEGY
10.7.4 RECENT DEVELOPMENTS
10.7.5 SWOT ANALYSIS
10.8 JOHNSON AND JOHNSON
10.8.1 BUSINESS OVERVIEW
10.8.2 PRODUCTS & SERVICES
10.8.3 KEY STRATEGY
10.8.4 RECENT DEVELOPMENTS
10.8.5 SWOT ANALYSIS
10.9 MEDIMMUNE, LLC
10.9.1 BUSINESS OVERVIEW
10.9.2 PRODUCTS & SERVICES
10.9.3 KEY STRATEGY
10.9.4 RECENT DEVELOPMENTS
10.9.5 SWOT ANALYSIS
10.10 ATELLAS PHARMA, INC
10.10.1 BUSINESS OVERVIEW
10.10.2 PRODUCTS & SERVICES
10.10.3 KEY STRATEGY
10.10.4 RECENT DEVELOPMENTS
10.10.5 SWOT ANALYSIS
10.11 SERUM INSTITUTE OF INDIA
10.11.1 BUSINESS OVERVIEW
10.11.2 PRODUCTS & SERVICES
10.11.3 KEY STRATEGY
10.11.4 RECENT DEVELOPMENTS
10.11.5 SWOT ANALYSIS
10.12 BAVARIAN NORDIC
10.12.1 BUSINESS OVERVIEW
10.12.2 PRODUCTS & SERVICES
10.12.3 KEY STRATEGY
10.12.4 RECENT DEVELOPMENTS
10.12.5 SWOT ANALYSIS
10.13 MITSUBISHI TANABE PHARMA CORPORATION
10.13.1 BUSINESS OVERVIEW
10.13.2 PRODUCTS & SERVICES
10.13.3 KEY STRATEGY
10.13.4 RECENT DEVELOPMENTS
10.13.5 SWOT ANALYSIS
10.14 DAIICHI SANKYO COMPANY, LIMITED
10.14.1 BUSINESS OVERVIEW
10.14.2 PRODUCTS & SERVICES
10.14.3 KEY STRATEGY
10.14.4 RECENT DEVELOPMENTS
10.14.5 SWOT ANALYSIS
